EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Austar Lifesciences Limited (AULSF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Austar Lifesciences Limited $0.05, price $0.02, upside +150.0%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · Home Hong Kong

AL Austar Lifesciences Limited logo Thin data Sep 24, 2026

Austar Lifesciences Limited

AULSF · US

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value $0.0500 · Strongly undervalued (+150.0%)
!Quality 56/100
!Weak Growth (revenue 5y +3.4 %/yr)
!Thin margins · 2.2% net margin (TTM)
✓Low debt · generates free cash flow
✓Ranks above peers (6/10)
!Narrow moat 22/100
!Evidence only low, so the estimate is less certain
!Weak on past: 16 out of 100
Watch Austar Lifesciences Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$2.10 $0.0007 Fair Value $0.0500 Jan 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

32‑month range $0.0007 – $2.10 · fair‑value band $0.0420 – $0.0580 · the $0.0200 price screens below the $0.0500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Austar Lifesciences in your weekly email

Every Wednesday you see whether Austar Lifesciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally.

Show more

Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through Integrated Process and Packaging Equipment & Systems (IPS); Consulting, Digitalization and Construction (CDC); and Life Science Equipment and Consumables (SIC) segments. The company also offers clean utility equipment and chemical pharmaceutical preparation systems; bioprocess equipment and systems; clean room, automation control, and monitoring systems; powder and solid equipment and systems; aseptic freeze-drying, filling, and visual inspection solutions; pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; and laboratory one-stop solutions. In addition, it provides consulting and engineering technical services; compliance and validation services; digital factory services; clean room HVAC/EMS/BMS services; and upgrade, retrofit, and maintenance services. Further, it engages in life science consumables, advanced therapies, and advanced bioprocessing technologies, as well as engineering design services. Austar Lifesciences Limited was founded in 1991 and is headquartered in Shanghai, China.

Stock analysis

Austar Lifesciences Limited (AULSF) currently trades at $0.0200, while our model-based Fair Value estimate is $0.0500, implying the stock looks roughly 60.0% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $0.3200 per share, and 22 of the 22 models we run sit above the $0.0200 price.

Bear case: the Earnings-Based group reads lowest at $0.0800, and 0 of the 22 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.0420 (bear) to $0.0580 (bull), the price of $0.0200 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Austar Lifesciences Limited reported revenue of 1.5B CNY in FY2025 versus 2.0B CNY in FY2021, a compound −6.6%/yr. Reported net income was 33.8M CNY in FY2025, compounding −40.9%/yr from FY2021.

Key figures

Market cap $35.9M · P/S ratio 0.02 · Net margin 2.2% · Return on equity 4.1% · Return on assets (EBIT) 2.8% · Operating margin 2.6% · Revenue (TTM) 1.5B CNY · Revenue growth (YoY) +8.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 71% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 150%, AULSF screens cheaper than that median.

Fair Value models

Bear $0.0420 Fair Value $0.0500 Bull $0.0580
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $0.3500 $0.4600 $0.6600 81
Growth DCF $0.3600 $0.4700 $0.6500 79
Owner Earnings $0.2200 $0.2800 $0.3900 77
All 22 models by family
DCF Models
FCF DCF $0.3500 $0.4600 $0.6600 81
Owner Earnings $0.2200 $0.2800 $0.3900 77
5Y Revenue Exit $0.2200 $0.2600 $0.3300 74
5Y EBITDA Exit $0.3000 $0.4000 $0.5400 76
5Y P/E Exit $0.2500 $0.3200 $0.4000 72
10Y Revenue Exit $0.2700 $0.3000 $0.3400 68
10Y EBITDA Exit $0.3200 $0.3900 $0.4600 70
10Y P/E Exit $0.2900 $0.3400 $0.3900 65
Earnings-Based
Graham-Dodd $0.0700 $0.0800 $0.0900 67
EPV $0.1200 $0.1300 $0.1400 71
Multiples
P/E Multiple $0.1600 $0.2200 $0.2700 63
P/S Multiple $0.1300 $0.1700 $0.2100 58
P/B Multiple $0.1300 $0.1700 $0.2100 55
EV/EBIT $0.1700 $0.2100 $0.2600 66
EV/EBITDA $0.3000 $0.3900 $0.4700 67
EV/Revenue $0.1400 $0.1800 $0.2100 54
Asset-Based
NCAV (Graham) $0.1200 $0.1600 $0.2400 54
Growth DCF
Growth DCF $0.3600 $0.4700 $0.6500 79
Rev-Margin DCF $0.2200 $0.2700 $0.3400 74
Economic Profit
Residual Income $0.1800 $0.1800 $0.1900 71
ROIC Compounder $0.1200 $0.1300 $0.1400 72
Growth Earnings
Growth-Adj P/E $0.1100 $0.1600 $0.2100 67

Open the full fair value analysis →

Notify me when AULSF reaches fair value

Put AULSF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 56/100

Of which business quality 55 · Market factors (momentum, volatility) 11

Profitability 30
Margins and returns on capital today
Quality Growth 43
Are margins and returns improving?
Cashflow 62
Earnings quality: real cash, not paper profit
Fin. Strength 39
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 37
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.4%
Start year 2020 (pandemic)
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−26.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−26.3%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 2%

Watch AULSF, get fair value alerts →

Compare Austar Lifesciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 349 stocks

Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 56 · Above median
Fair Value upside +136.1% · Top 25%
Profitability
Return on equity (TTM) 4.1% · Above median
Return on assets 1.3% · Below median
Net margin (TTM) 2.2% · Below median
Operating margin (TTM) 2.6% · Below median
Growth and dividend
Revenue growth 8.7% · Above median
Balance sheet
Debt / equity 0.08× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/S (TTM) 0.02× · Cheapest 25%
P/FCF 0.4× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 9
FUTURE (revenue growth)44 · sector 31
PAST (return on equity)16 · sector 11
HEALTH (low debt)96 · sector 97
DIVIDEND (yield)0 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Boston Scientific Corporation BSX $43.65 $48.02 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Austar Lifesciences Limited · Fair Value
$0.0500 +60%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Austar Lifesciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/AULSF

Frequently asked questions

Is Austar Lifesciences Limited (AULSF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.0500 versus the last price from Sep 25, 2026 of $0.0200, about +150% upside (undervalued).
What is the fair value of AULSF?
Our model-based fair value for Austar Lifesciences Limited is $0.0500 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0200.
What is the quality score of AULSF?
Austar Lifesciences Limited has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Austar Lifesciences Limited (AULSF)?
Our model-based price target is the fair value of $0.0500 (as of Sep 24, 2026) from 22 valuation models. Cautious scenario $0.0420, optimistic scenario $0.0580. It is a calculation from audited fundamentals, not an analyst target.
What is the Austar Lifesciences Limited stock forecast for 2026?
Our models put fair value at $0.0500, about +150% upside versus the last price from Sep 25, 2026 of $0.0200 (undervalued). Cautious scenario $0.0420, optimistic scenario $0.0580. The calculation is refreshed regularly with new filings.
What is the revenue of Austar Lifesciences Limited (AULSF)?
Austar Lifesciences Limited reported trailing-twelve-month revenue of about 1.5B CNY (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Austar Lifesciences Limited (AULSF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Austar Lifesciences Limited it is $0.0500 per share (as of Sep 24, 2026), against a price of $0.0200. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Austar Lifesciences Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, AULSF trades below its calculated fair value: price $0.0200, fair value $0.0500, a gap of about +150% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AULSF?
No. The price is what the market pays today ($0.0200); the fair value is what the company's own numbers justify ($0.0500). For Austar Lifesciences Limited the two are $0.0300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Austar Lifesciences Limited worth?
The market values Austar Lifesciences Limited at about $35.9M (market capitalisation, as of Sep 24, 2026). Per share that is $0.0200; our models calculate a fair value of $0.0500 per share.
What do the bullish and bearish scenarios say about AULSF?
Our models span a range for Austar Lifesciences Limited: cautious scenario $0.0420, base $0.0500, optimistic $0.0580 per share (as of Sep 24, 2026, price $0.0200). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Austar Lifesciences Limited (AULSF)?
Balance-sheet figures for Austar Lifesciences Limited (as of Sep 24, 2026): return on equity 4.1%, debt of 0.08 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is AULSF from its 52-week high?
Austar Lifesciences Limited trades at $0.0200, about 71% below its 52-week high of $0.0700 and at the low of $0.0200 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0500 is for.
Which stocks are comparable to Austar Lifesciences Limited?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Austar Lifesciences Limited stock attractive at the current price?
The data as of Sep 24, 2026: price $0.0200, calculated fair value $0.0500 (+150%), Quality Score 56/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AULSF calculated?
We run Austar Lifesciences Limited through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Austar Lifesciences Limited currently trades 60 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Austar Lifesciences Limited (AULSF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0200. Our model-based fair value is $0.0500, about +150% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Austar Lifesciences Limited right now?
The price is below even our cautious bear case ($0.0420). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Austar Lifesciences Limited

How large is the market capitalisation of Austar Lifesciences Limited (AULSF)?
The market capitalisation of Austar Lifesciences Limited is $35.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Austar Lifesciences Limited (AULSF)?
The price-to-sales ratio of Austar Lifesciences Limited is 0.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Austar Lifesciences Limited (AULSF)?
The net margin of Austar Lifesciences Limited is 2.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Austar Lifesciences Limited (AULSF)?
The return on equity (ROE) of Austar Lifesciences Limited is 4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Austar Lifesciences Limited (AULSF)?
On an EBIT basis the return on assets of Austar Lifesciences Limited is 2.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Austar Lifesciences Limited (AULSF)?
The operating margin of Austar Lifesciences Limited is 2.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Austar Lifesciences Limited (AULSF)?
Revenue at Austar Lifesciences Limited is growing +8.7% versus a year earlier (3y avg −10.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Austar Lifesciences Limited (AULSF)?
Earnings per share at Austar Lifesciences Limited are growing −19.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Austar Lifesciences Limited (AULSF) generate?
The free cash flow of Austar Lifesciences Limited is 102M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Austar Lifesciences Limited (AULSF) carry?
The net debt of Austar Lifesciences Limited is 94.2M CNY (fiscal year 2025, ≈ 0.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Austar Lifesciences Limited in the live analysis

One click puts Austar Lifesciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.